

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

In re Patent Application of:  
Jordan J. N. TANG et al.

Application No.: 10/820,953

Confirmation No.: 9733

Filed: April 8, 2004

Art Unit: 1654

For: INHIBITORS OF MEMAPSYN 2 AND USE  
THEREOF

---

Examiner: A. Mohamed

**AMENDMENT UNDER 37 CFR 1.312**

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Amendment under 37 C.F.R. §1.312 is submitted after the mailing of a Notice of Allowance for the above-referenced patent application, and before the payment of the Issue Fee. Accordingly, this Amendment is timely filed. The Applicants note that co-filed herewith are a Statement Pursuant to 37 CFR § 1.821(f), Substitute Sequence Listing, and Communication Regarding Fee Deficiency Related to Entity Status and Notice of Status under 37 C.F.R. §1.28(C). A replacement copy of Figure 5(A-E) is also provided herewith.

Please amend the **specification and claims** in adherence with 37 C.F.R. §§ 1.821-1.825 and in response to the Examiner's Amendment as described beginning on page 2 (specification) and page 8 (claims) of this paper.

**Remarks** begin on page 10 of this paper.